Sanofi's New Leadership Faces Looming Patent Cliff
Sanofi's wide lineup of branded drugs and vaccines and robust pipeline creates strong cash flows and a narrow economic moat.
Sanofi SA ADR SNY
Bulls Say, Bears Say
Bulls
Immunology drug Dupixent holds strong pricing power and market share across several indications.
Bears
Sanofi suffered several disappointing readouts starting in 2025, adding pressure to develop or acquire assets that could replace Dupixent before its loss of exclusivity.
News
The world's most sophisticated drug companies are putting billions into vaccines - despite the political environment
Nurix Therapeutics Shares Plunge on Sanofi's Termination of Drug Development Program
Regeneron Pharma 3Q Sales Climb on Dupixent Growth
Sanofi CEO Sets Sights on Deals to Drive Turnaround — 2nd Update
Sanofi CEO Sets Sights on Deals to Drive Turnaround — Update
Sanofi CEO Sets Sights on Deals to Drive Turnaround
UEG Week: Teva and Sanofi’s Duvakitug Maintained Long-Term Positive Outcomes in New Phase 2b Data for Ulcerative Colitis and Crohn’s Disease
EU Accepts Sanofi's Concessions to End Antitrust Probe Over Vaccine Marketing — Update
Articles & Videos
Trading Information
- Previous Close Price
- $48.43
- Day Range
- $48.50–48.92
- 52-Week Range
- $39.08–52.68
- Bid/Ask
- $48.74 / $48.76
- Shares Outstanding
- 2.40B
- Market Cap
- $116.81B
- Volume/Avg
- 502,781 / 3M
Key Statistics
- Price/Earnings (Normalized)
- 12.55
- Price/Sales
- 1.97
- Dividend Yield (Trailing)
- 4.99%
- Dividend Yield (Forward)
- 4.99%
- Dividend Payment Schedule
- Jun
- Total Yield
- 9.72%
Company Profile
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest-revenue product, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Large Value
- Total Number of Employees
- 74,846
- Website
- https://www.sanofi.com
Competitors
Valuation
Metric | SNY | NVS | MRK |
|---|---|---|---|
Price/Earnings (Normalized) | 12.55 | 16.35 | 109.34 |
Price/Book Value | 1.40 | 8.13 | 8.09 |
Price/Sales | 1.97 | 5.36 | 5.41 |
Price/Cash Flow | 8.41 | 15.75 | 16.45 |
Price/Earnings
SNY
NVS
MRK
Financial Strength
Metric | SNY | NVS | MRK |
|---|---|---|---|
Quick Ratio | 0.21 | 0.58 | 0.78 |
Current Ratio | 1.12 | 0.88 | 1.35 |
Interest Coverage | 9.10 | 8.78 | 3.33 |
Quick Ratio
SNY
NVS
MRK
Profitability
Metric | SNY | NVS | MRK |
|---|---|---|---|
Return on Assets (Normalized) | 8.44% | 14.70% | 2.53% |
Return on Equity (Normalized) | 15.62% | 40.76% | 7.02% |
Return on Invested Capital (Normalized) | 12.02% | 21.22% | 4.79% |
Return on Assets
SNY
NVS
MRK
Drug Manufacturers - General Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Eli Lilly and Co LLY | LOCK|XL^<@dh | LOCK|j^# | $1T | |||
| Johnson & Johnson JNJ | LOCK|BVY$&B! | LOCK|#v | $675B | |||
| AbbVie Inc ABBV | LOCK|#H%<n& | LOCK|p<g | $521B | |||
| Roche Holding AG ADR RHHBY | LOCK|^J#gL#R | LOCK|>D | $389B | |||
| Merck & Co Inc MRK | LOCK|zc@G$% | LOCK|Yp | $363B | |||
| Novartis AG ADR NVS | LOCK|<BgsP%& | LOCK|?Xs | $304B | |||
| AstraZeneca PLC AZN | LOCK|Btg>n$< | LOCK|#^ | $288B | |||
| Amgen Inc AMGN | LOCK|<vQ%<w#l | LOCK|Fv | $253B | |||
| Gilead Sciences Inc GILD | LOCK|sXk>%gB | LOCK|&MW | $211B | |||
| Novo Nordisk AS ADR NVO | LOCK|?&p&n$H | LOCK|f!Q | $180B |
United States